Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Contract termination · Investor press release
Cardiff Oncology, Inc.
32
Contract termination
Jun 3, 2026
| Item 1.02 | Terminated a material definitive agreement |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
Cardiff Oncology, Inc. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
June 3, 2026 Interim Results from the Randomized, Controlled Phase 2 CRDF-004 Trial Onvansertib + SoC Chemo/Bevacizumab in First-Line RAS-Mutated mCRC Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, pl…
This filing reports Item 1.02 (terminated a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Cardiff Oncology, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
